ALNYLAM PHARMACEUTICALS, INC. (ALNY)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 1.5B 3B 4.5B Q4 '09: 100.5M Q1 '10: 100M Q2 '10: 102.1M Q3 '10: 105.5M Q4 '10: 100M Q1 '11: 96.4M Q4 '17: 89.9M Q1 '18: 92.9M Q2 '18: 106.8M Q3 '18: 91.8M Q4 '18: 74.9M Q1 '19: 86.3M Q2 '19: 101.1M Q3 '19: 169.1M Q4 '19: 219.8M Q1 '20: 285.9M Q2 '20: 345.2M Q3 '20: 401M Q4 '20: 492.9M Q1 '21: 570.9M Q2 '21: 687.5M Q3 '21: 749.3M Q4 '21: 844.3M Q1 '22: 880M Q2 '22: 884.2M Q3 '22: 960.9M Q4 '22: 1B Q1 '23: 1.1B Q2 '23: 1.2B Q3 '23: 1.7B Q4 '23: 1.8B Q1 '24: 2B Q2 '24: 2.3B Q3 '24: 2.1B Q4 '24: 2.2B Q1 '25: 2.3B Q2 '25: 2.5B Q3 '25: 3.2B Q4 '25: 3.7B Q3 '10 Q2 '18 Q3 '19 Q4 '20 Q1 '22 Q2 '23 Q3 '24 Q4 '25

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-1.1B -700M -350M 0 350M 700M 1.1B Q4 '09: -48.1M Q1 '10: -51.4M Q2 '10: -40.7M Q3 '10: -39.7M Q4 '10: -44.1M Q1 '11: -48.4M Q2 '11: -49.9M Q3 '11: -53.6M Q4 '11: -54.8M Q1 '12: -50M Q2 '12: -49M Q3 '12: -54.7M Q4 '12: -129.5M Q1 '13: -128.4M Q2 '13: -137.6M Q3 '13: -151.7M Q4 '13: -92.9M Q1 '14: -352.2M Q2 '14: -375.9M Q3 '14: -388.9M Q4 '14: -405M Q1 '15: -188.1M Q2 '15: -216.1M Q3 '15: -249.2M Q4 '15: -296M Q1 '16: -353.8M Q2 '16: -373.3M Q3 '16: -401.7M Q4 '16: -424.6M Q1 '17: -421.1M Q2 '17: -449.1M Q3 '17: -468.2M Q4 '17: -500.1M Q1 '18: -541M Q2 '18: -612.9M Q3 '18: -741.6M Q4 '18: -814.7M Q1 '19: -856.1M Q2 '19: -900M Q3 '19: -861.7M Q4 '19: -939.4M Q1 '20: -960.8M Q2 '20: -923.4M Q3 '20: -932.3M Q4 '20: -828.4M Q1 '21: -804.5M Q2 '21: -751.8M Q3 '21: -708.3M Q4 '21: -708.7M Q1 '22: -669.1M Q2 '22: -714.7M Q3 '22: -791M Q4 '22: -785.1M Q1 '23: -788.1M Q2 '23: -826.3M Q3 '23: -354.4M Q4 '23: -282.2M Q1 '24: -175.8M Q2 '24: 102.6M Q3 '24: -188.1M Q4 '24: -176.9M Q1 '25: -115.4M Q2 '25: -180.2M Q3 '25: 264.7M Q4 '25: 501.6M Q1 '10 Q2 '12 Q3 '14 Q4 '16 Q1 '19 Q2 '21 Q3 '23 Q4 '25

Net Income TTM

-1.5B -1B -500M 0 500M 1B 1.5B Q4 '09: -47.6M Q1 '10: -52M Q2 '10: -44M Q3 '10: -44.4M Q4 '10: -43.5M Q1 '11: -47.5M Q2 '11: -46.7M Q3 '11: -50.3M Q4 '11: -57.6M Q1 '12: -52.7M Q2 '12: -51.9M Q3 '12: -58.1M Q4 '12: -106M Q1 '13: -103.7M Q2 '13: -108.9M Q3 '13: -119.1M Q4 '13: -89.2M Q1 '14: -331.2M Q2 '14: -357.1M Q3 '14: -371.4M Q4 '14: -360.4M Q1 '15: -160.2M Q2 '15: -187.9M Q3 '15: -220.7M Q4 '15: -290.1M Q1 '16: -342.3M Q2 '16: -360.6M Q3 '16: -387.9M Q4 '16: -410.1M Q1 '17: -414.4M Q2 '17: -442.7M Q3 '17: -461.6M Q4 '17: -490.9M Q1 '18: -524.8M Q2 '18: -569.9M Q3 '18: -692.3M Q4 '18: -761.5M Q1 '19: -802.2M Q2 '19: -858.1M Q3 '19: -821.4M Q4 '19: -886.1M Q1 '20: -886.4M Q2 '20: -846.2M Q3 '20: -890.9M Q4 '20: -858.3M Q1 '21: -876.4M Q2 '21: -886.7M Q3 '21: -837.9M Q4 '21: -852.8M Q1 '22: -892.9M Q2 '22: -980.7M Q3 '22: -1.2B Q4 '22: -1.1B Q1 '23: -1.1B Q2 '23: -1.1B Q3 '23: -509.9M Q4 '23: -440.2M Q1 '24: -332.1M Q2 '24: -72.9M Q3 '24: -332.3M Q4 '24: -278.2M Q1 '25: -230.5M Q2 '25: -285.8M Q3 '25: 76.8M Q4 '25: 272.1M Q1 '26: 496.4M Q2 '26: 733.1M Q3 '10 Q4 '12 Q1 '15 Q2 '17 Q3 '19 Q4 '21 Q1 '24 Q2 '26

Cost of Revenue TTM

0 250M 500M 750M Q2 '19: 9.5M Q3 '19: 14.6M Q4 '19: 25.1M Q1 '20: 35M Q2 '20: 49M Q3 '20: 64.6M Q4 '20: 74.2M Q1 '21: 83.9M Q2 '21: 95.9M Q3 '21: 103.2M Q4 '21: 115M Q1 '22: 115.4M Q2 '22: 119.2M Q3 '22: 127.6M Q4 '22: 140.2M Q1 '23: 158.1M Q2 '23: 199.4M Q3 '23: 242.4M Q4 '23: 268.2M Q1 '24: 281.4M Q2 '24: 273.3M Q3 '24: 275.8M Q4 '24: 306.5M Q1 '25: 322.1M Q2 '25: 396.8M Q3 '25: 512.1M Q4 '25: 677.2M Q4 '19 Q4 '20 Q4 '21 Q4 '22 Q4 '23 Q4 '24 Q4 '25

Operating Cash Flow TTM

-900M -600M -300M 0 300M 600M 900M Q2 '10: -77.4M Q3 '10: -80.8M Q4 '10: -84.3M Q1 '11: -75M Q2 '11: -77.3M Q3 '11: -82.3M Q4 '11: -87.1M Q1 '12: -111M Q2 '12: -106.1M Q3 '12: -71.9M Q4 '12: -115.6M Q1 '13: -86.4M Q2 '13: -88.3M Q3 '13: -115.2M Q4 '13: -68.7M Q1 '14: -109.4M Q2 '14: -132.4M Q3 '14: -151.4M Q4 '14: -165.6M Q1 '15: -150.2M Q2 '15: -159.1M Q3 '15: -172.7M Q4 '15: -189.1M Q1 '16: -246.5M Q2 '16: -261.3M Q3 '16: -282.4M Q4 '16: -307.7M Q1 '17: -324.4M Q2 '17: -335.3M Q3 '17: -358.1M Q4 '17: -382.8M Q1 '18: -438.1M Q2 '18: -459.8M Q3 '18: -515.2M Q4 '18: -562.6M Q1 '19: -595.5M Q2 '19: -204.1M Q3 '19: -232.9M Q4 '19: -278.4M Q1 '20: -336.1M Q2 '20: -760.1M Q3 '20: -687.8M Q4 '20: -615M Q1 '21: -604.5M Q2 '21: -591M Q3 '21: -614.7M Q4 '21: -641.7M Q1 '22: -577.2M Q2 '22: -578.2M Q3 '22: -559.4M Q4 '22: -541.3M Q1 '23: -536.6M Q2 '23: -472.7M Q3 '23: 2M Q4 '23: 104.2M Q1 '24: 189.1M Q2 '24: 372.3M Q3 '24: 56.6M Q4 '24: -8.3M Q1 '25: -45.1M Q2 '25: -41.5M Q3 '25: 265.9M Q4 '25: 524.1M Q4 '11 Q4 '13 Q4 '15 Q4 '17 Q4 '19 Q4 '21 Q4 '23 Q4 '25

Free Cash Flow TTM

-900M -600M -300M 0 300M 600M 900M Q2 '10: -81.9M Q3 '10: -85.7M Q4 '10: -89.1M Q1 '11: -78.7M Q2 '11: -80M Q3 '11: -84.2M Q4 '11: -88.4M Q1 '12: -112.5M Q2 '12: -108.8M Q3 '12: -80M Q4 '12: -124M Q1 '13: -96.2M Q2 '13: -96.9M Q3 '13: -119M Q4 '13: -72.7M Q1 '14: -112M Q2 '14: -136.5M Q3 '14: -157.7M Q4 '14: -174.6M Q1 '15: -160.9M Q2 '15: -169.1M Q3 '15: -186.1M Q4 '15: -202.1M Q1 '16: -260.1M Q2 '16: -295.2M Q3 '16: -330.2M Q4 '16: -372.3M Q1 '17: -422.4M Q2 '17: -433.2M Q3 '17: -461.4M Q4 '17: -487M Q1 '18: -527.4M Q2 '18: -550.1M Q3 '18: -625.3M Q4 '18: -689.5M Q1 '19: -745.1M Q2 '19: -352.3M Q3 '19: -371.8M Q4 '19: -418.6M Q1 '20: -451.8M Q2 '20: -871.2M Q3 '20: -775.3M Q4 '20: -685.3M Q1 '21: -672.4M Q2 '21: -653.5M Q3 '21: -690.9M Q4 '21: -718.1M Q1 '22: -654.3M Q2 '22: -660.1M Q3 '22: -631.7M Q4 '22: -613.3M Q1 '23: -604.6M Q2 '23: -540.7M Q3 '23: -66.6M Q4 '23: 41.9M Q1 '24: 127.8M Q2 '24: 318.9M Q3 '24: 16.1M Q4 '24: -42.6M Q1 '25: -75.4M Q2 '25: -78M Q3 '25: 221.4M Q4 '25: 465.4M Q4 '11 Q4 '13 Q4 '15 Q4 '17 Q4 '19 Q4 '21 Q4 '23 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 50M 100M 150M Q2 '20: 114.9M Q3 '20: 116M Q1 '21: 117.1M Q2 '21: 117.8M Q3 '21: 119.1M Q1 '22: 120.4M Q2 '22: 120.9M Q3 '22: 122.2M Q1 '23: 124.1M Q2 '23: 124.7M Q3 '23: 131.3M Q1 '24: 126.1M Q2 '24: 126.7M Q3 '24: 128.6M Q1 '25: 129.7M Q2 '25: 130.6M Q3 '25: 137.3M Q2 '26: 138.3M Q1 '21 Q1 '22 Q1 '23 Q1 '24 Q1 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-10.50 -7.00 -3.50 0.00 3.50 7.00 10.50 Q4 '10: -1.04 Q1 '11: -1.13 Q2 '11: -1.11 Q3 '11: -1.19 Q4 '11: -1.35 Q1 '12: -1.22 Q2 '12: -1.14 Q3 '12: -1.21 Q4 '12: -2.08 Q1 '13: -1.98 Q2 '13: -2.02 Q3 '13: -2.12 Q4 '13: -1.43 Q1 '14: -4.98 Q2 '14: -5.27 Q3 '14: -5.37 Q4 '14: -5.14 Q1 '15: -2.06 Q2 '15: -2.33 Q3 '15: -2.66 Q4 '15: -3.45 Q1 '16: -4.04 Q2 '16: -4.24 Q3 '16: -4.54 Q4 '16: -4.79 Q1 '17: -4.83 Q2 '17: -5.12 Q3 '17: -5.25 Q4 '17: -5.41 Q1 '18: -5.57 Q2 '18: -5.86 Q3 '18: -6.95 Q4 '18: -7.56 Q1 '19: -7.88 Q2 '19: -8.27 Q3 '19: -7.76 Q4 '19: -8.14 Q1 '20: -8.03 Q2 '20: -7.57 Q3 '20: -7.83 Q4 '20: -7.45 Q1 '21: -7.54 Q2 '21: -7.59 Q3 '21: -7.13 Q4 '21: -7.20 Q1 '22: -7.49 Q2 '22: -8.17 Q3 '22: -9.77 Q4 '22: -9.29 Q1 '23: -8.69 Q2 '23: -8.61 Q3 '23: -4.14 Q4 '23: -3.55 Q1 '24: -2.67 Q2 '24: -0.59 Q3 '24: -2.61 Q4 '24: -2.17 Q4 '10 Q4 '12 Q4 '14 Q4 '16 Q4 '18 Q4 '20 Q4 '22 Q4 '24

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.